Saving the bones in breast cancer: aromatase inhibitor-induced osteoporosis

References

• Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res. Treat. 107(3), 309–330 (2008).
   PubMed Web of Science ®Google Scholar
• Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Oncol. Pract. 6(4), 195–197 (2010).
   PubMedGoogle Scholar
• Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocr. Rev. 26(3), 331–345 (2005).
   PubMed Web of Science ®Google Scholar
• Perez EA, Josse RG, Pritchard KI et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J. Clin. Oncol. 24(22), 3629–3635 (2006).
   PubMed Web of Science ®Google Scholar
• Sestak I, Cuzick J, Sapunar F et al.; ATAC Trialists’ Group. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol. 9(9), 866–872 (2008).
   PubMed Web of Science ®Google Scholar
• Rabaglio M, Sun Z, Price KN et al.; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann. Oncol. 20(9), 1489–1498 (2009).
   PubMed Web of Science ®Google Scholar
• Jakesz R, Jonat W, Gnant M et al.; ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366(9484), 455–462 (2005).
   PubMed Web of Science ®Google Scholar
• Coombes RC, Kilburn LS, Snowdon CF et al.; Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561), 559–570 (2007).
   PubMed Web of Science ®Google Scholar
• Reginster JY, Collette J, Neuprez A, Zegels B, Deroisy R, Bruyere O. Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy. Bone 42(5), 832–836 (2008).
   PubMedGoogle Scholar
• Coleman RE, Banks LM, Girgis SI et al.; Intergroup Exemestane Study group. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 8(2), 119–127 (2007).
   PubMed Web of Science ®Google Scholar
• Lønning PE, Geisler J, Krag LE et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J. Clin. Oncol. 23(22), 5126–5137 (2005).
   PubMed Web of Science ®Google Scholar
• Eastell R, Van Poznak C, Hannon R et al. The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month results. J. Bone Miner. Res. 22(1), S113 (2007).
   Google Scholar
• Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 41(3), 346–352 (2007).
   PubMed Web of Science ®Google Scholar
• Lester JE, Dodwell D, Purohit OP et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin. Cancer Res. 14(19), 6336–6342 (2008).
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Schippinger W et al.; ABCSG-12 Trial Investigators. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360(7), 679–691 (2009).
   PubMed Web of Science ®Google Scholar
• Brufsky A, Harker WG, Beck JT et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J. Clin. Oncol. 25(7), 829–836 (2007).
   PubMed Web of Science ®Google Scholar
• Bundred NJ, Campbell ID, Davidson N et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 112(5), 1001–1010 (2008).
   PubMed Web of Science ®Google Scholar
• Schenk N, Llombart A, Frassoladti A et al. The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole (Let). Eur. J. Cancer. 5, 186 (2007).
   Web of Science ®Google Scholar
• Ellis GK, Bone HG, Chlebowski R et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J. Clin. Oncol. 26(30), 4875–4882 (2008).
   PubMed Web of Science ®Google Scholar
• Saarto T, Blomqvist C, Välimäki M, Mäkelä P, Sarna S, Elomaa I. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br. J. Cancer 75(4), 602–605 (1997).
   PubMed Web of Science ®Google Scholar